Advances in regenerative cardiology: Stem cells versus bioartificial tissues
Authors:
- Jenyfer María Fuentes‐MendozaJFJenyfer María Fuentes‐Mendoza
- Juan Muñoz‐MorenoJMJuan Muñoz‐Moreno
- Marcio Concepción‐ZavaletaMCMarcio Concepción‐Zavaleta
- Luis Concepción‐UrteagaLCLuis Concepción‐Urteaga
- José Paz‐IbarraJPJosé Paz‐Ibarra
- Roger Gonzales‐ValdiviesoRGRoger Gonzales‐Valdivieso
- Fernanda Ginebra Castillo‐VelásquezFCFernanda Ginebra Castillo‐Velásquez
- Angie Sofía Burgos‐CastilloABAngie Sofía Burgos‐Castillo
- Regina Garza‐BoullosaRGRegina Garza‐Boullosa
- Vanesa Daniela Núñez‐PérezVNVanesa Daniela Núñez‐Pérez
- 22 July 2025
- journal article
- review article
- Published by Wiley in European Journal of Clinical Investigation
- p. e70101
Abstract
Background: Cardiovascular disease (CVD) remains the leading cause of mortality worldwide. The human myocardium has a limited regenerative capacity, prompting the development of innovative strategies to restore cardiac function. Stem cells (SCs) and bioartificial tissues (BATs) have emerged as promising tools in regenerative cardiology for myocardial repair and functional recovery.Methods: This review analyzes current preclinical and clinical research focused on SC‐ and BAT‐based therapies for CR. Literature was identified through comprehensive database searches. Studies evaluating cardiomyocyte differentiation, integration into host tissue, vascularisation and electromechanical properties were selected. Emphasis was placed on therapeutic potential, safety and translational challenges.Results: SCs, including embryonic and mesenchymal stem cells, demonstrated potential to differentiate into cardiomyocyte‐like cells and contribute to myocardial restoration. When combined with biomaterial scaffolds or decellularized matrices, SCs showed improved survival, structural support, and functional integration. BATs, such as engineered heart tissue, replicated native myocardial architecture and supported synchronized contraction. Despite these advances, concerns persist regarding immunogenicity, arrhythmias, and long‐term efficacy. Technical hurdles in large‐scale production and personalised application remain unresolved.Conclusions: SC‐ and BAT‐based therapies offer innovative avenues for repairing damaged myocardium. Their application could revolutionise treatment strategies for heart failure and post‐infarction remodelling. However, clinical translation requires addressing immune compatibility, arrhythmic risk and manufacturing limitations. Interdisciplinary collaboration and regulatory standardisation are essential for their future clinical adoption.Keywords
This publication has 92 references indexed in Scilit:
- Electromagnetic Cellularized Patch with Wirelessly Electrical Stimulation for Promoting Neuronal Differentiation and Spinal Cord Injury RepairAdvanced Science, 2024
- Combinatorial Effect of Biomaterials and Extracellular Vesicle Therapy for Heart Failure with Reduced Ejection Fraction: A Systematic Review of Preclinical StudiesAdvanced Healthcare Materials, 2023
- Cardiac Regeneration After Myocardial Infarction: an Approachable GoalCurrent Cardiology Reports, 2020
- Heart Failure With Reduced Ejection FractionJAMA, 2020
- Epidemiology of Heart FailureEuropean Journal of Heart Failure, 2020
- Highlights in Heart FailureESC Heart Failure, 2019
- Survival of Patients with Chronic Heart Failure in the Community: A Systematic Review and Meta-AnalysisEuropean Journal of Heart Failure, 2019
- Postnatal Cardiac Development and Regenerative Potential in Large MammalsPediatric Cardiology, 2019
- The Various Applications of 3D Printing in Cardiovascular DiseasesCurrent Cardiology Reports, 2018
- Stem Cells in Regenerative Cardiology2017